Farmas USA

Dynavax Tech's lead candidate combined with Keytruda shows positive action in early-stage studies

Apr. 16, 2018 3:40 PM ET|About:  Dynavax Technologies C... (DVAX)|By:  Douglas W. House, SA News Editor 

Dynavax Technologies' ( DVAX -6.8%) lead candidate SD-101, combined with Merck's ( MRK +2.6%) KEYTRUDA (pembrolizumab), showed  positive effectsin early-stage studies in head-and-neck cancer and melanoma. The data are being presented at the American Association for Cancer Research Annual Meeting in Chicago.

Preliminary results from a Phase 1b/2 study in patients with advanced head-and-neck squamous cell carcinoma showed showed an objective response rate (ORR) of 33% (n=6/18) with no dose-limiting toxicities.

Preliminary data from a Phase 1b/2 study in advanced melanoma showed that 86% of the initial responses were sustained after a median of 18 months (n=6/7) in patients not previously treated with a PD-1 inhibitor. 17% (n=2/12) of evaluable patients who progressed on prior anti-PD-1 therapy achieved partial or stable disease for at least 10.5 months.

Median progression-free survival (PFS), duration of response and median overall survival (OS) have not been reached.

Previously:  Combination of Dynavax's SD-101 and Keytruda show 100% response in melanoma study; shares ahead 4% after hours (June 2, 2017)

https://seekingalpha.com/news/3345922-dynavax-techs-lead-candidate-combined-keytruda-shows-positive-action-early-stage-studies

-----

En 2017 dijeron que 100%, ahora que 86 % y que no se ha alcanzado la tasa media de supervivencia  libre de progresion 

CLDX ánimo Mugi

Sanofi to sell generics arm for €1.9B

to private equity firm Advent International for €1.9B.

That's after spending more than $16B to buy biotech company Ablynx and U.S. haemophilia specialist Bioverativ.

This week, Sanofi also sold some brands to Charterhouse Capital Partners' Cooper-Vemedia drugs manufacturing arm for €158M.

https://seekingalpha.com/news/3345998-sanofi-sell-generics-arm-1_9b?ifp=0

ADXS

Sobre la presentación de ayer

Advaxis (ADXS) Says Preclinical Data Highlighting ADXS-Hot as Immunotherapy Presented in Poster Discussion at AACR

poster discussion entitled “Targeting Shared Hotspot Cancer Mutations with a Listeria monocytogenes Immunotherapy Induce Potent Anti-Tumor Immunity” at the American Association for Cancer Research (AACR) Annual Meeting underway in Chicago.The ADXS-HOT franchise leverages the Company’s proprietary Lm Technology to target common mutations in tumor driver genes.

This study’s objective was to identify and target common (public or shared) mutations (hotspots) and to determine if the ADXS-HOT platform could effectively target those hotspots and control tumor growth. Results indicate that ADXS-HOT could achieve this in preclinical models against single and multi-target constructs.

The full abstract is available here: http://https://www.advaxis.com/wp-content/uploads/2018/04/HOT-AACR-Abstract-Final-2018.pdf

“The results of this preclinical work with ADXS-HOT represent an exciting opportunity that may allow us to develop disease-specific immunotherapies that have the potential to be effective against multiple targets, capable of generating high-avidity T cells against shared of public mutations, as well as multiple proprietary highly immunogenic cancer-testes and oncofetal antigens for multiple tumor types,” said Robert G. Petit, Ph.D., Executive Vice President and Chief Scientific Officer of Advaxis. “Additionally, the results show increased functionality and resiliency in CD8 T cells upon restimulation, indicating the potential not only to increase the number and frequency of CD8 T cells, but to strengthen them.”

NVIV

R/S 1:25 y de momento pierde poco (claro que lleva un varapalo tremendo)... Market cap cerca de los 12milloncicos Al que le gusten las emociones fuertes chicharriles ahí tiene una.

NVIV

La verdad es que el producto es demasiado bonito, demasiado rompedor, para ser verdad...

NVIV

Uf, la diferencia entre el bid y el ask está a más de un pavo. ¡Qué miedo! Ya no es la misma de antes; ni yo tampoco ;)

NVIV

Y pensar que en marzo de 2015 tocó los $47... ajustado serían $1,175 (anda en $8 trás el R/S)